Jen‐Yu Hung

3.6k total citations
46 papers, 1.4k citations indexed

About

Jen‐Yu Hung is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jen‐Yu Hung has authored 46 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 20 papers in Molecular Biology and 20 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jen‐Yu Hung's work include Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (11 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Jen‐Yu Hung is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (11 papers) and Lung Cancer Diagnosis and Treatment (7 papers). Jen‐Yu Hung collaborates with scholars based in Taiwan, United States and South Korea. Jen‐Yu Hung's co-authors include Po‐Lin Kuo, Ya‐Ling Hsu, Kuan‐Li Wu, Ying‐Ming Tsai, Wei‐An Chang, Chi‐Tun Lien, Chih‐Jen Yang, Yi-Shiuan Lin, Shu‐Fang Jian and Yi‐Chung Pan and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Immunology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Jen‐Yu Hung

43 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jen‐Yu Hung Taiwan 18 788 570 439 363 276 46 1.4k
Xiang Long China 18 983 1.2× 660 1.2× 263 0.6× 187 0.5× 193 0.7× 46 1.3k
Jian Zhou China 22 858 1.1× 636 1.1× 367 0.8× 234 0.6× 142 0.5× 95 1.4k
Francesca Collina Italy 22 680 0.9× 428 0.8× 581 1.3× 141 0.4× 220 0.8× 49 1.3k
Fangxuan Li China 23 535 0.7× 404 0.7× 423 1.0× 326 0.9× 276 1.0× 55 1.3k
Jun Song China 23 990 1.3× 675 1.2× 449 1.0× 152 0.4× 175 0.6× 69 1.6k
Zhijun Zhou United States 20 662 0.8× 386 0.7× 441 1.0× 160 0.4× 240 0.9× 49 1.2k
Jun Qian China 19 1.1k 1.4× 936 1.6× 216 0.5× 394 1.1× 122 0.4× 45 1.7k
Mahdi Abdoli Shadbad Iran 22 558 0.7× 339 0.6× 569 1.3× 167 0.5× 454 1.6× 60 1.3k

Countries citing papers authored by Jen‐Yu Hung

Since Specialization
Citations

This map shows the geographic impact of Jen‐Yu Hung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jen‐Yu Hung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jen‐Yu Hung more than expected).

Fields of papers citing papers by Jen‐Yu Hung

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jen‐Yu Hung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jen‐Yu Hung. The network helps show where Jen‐Yu Hung may publish in the future.

Co-authorship network of co-authors of Jen‐Yu Hung

This figure shows the co-authorship network connecting the top 25 collaborators of Jen‐Yu Hung. A scholar is included among the top collaborators of Jen‐Yu Hung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jen‐Yu Hung. Jen‐Yu Hung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hung, Jen‐Yu, et al.. (2025). Immune-Based Therapies in Pancreatic Cancer: a Systematic Review of Ongoing Clinical Trials (2020–2022). Journal of Gastrointestinal Cancer. 56(1). 103–103.
2.
3.
Tsai, Ming‐Ju, Jen‐Yu Hung, Yu-Chen Tsai, et al.. (2023). Local Consolidative Therapy May Have Prominent Clinical Efficacy in Patients with EGFR-Mutant Advanced Lung Adenocarcinoma Treated with First-Line Afatinib. Cancers. 15(7). 2019–2019. 3 indexed citations
4.
5.
Wu, Kuan‐Li, Hsiao‐Ling Chen, Ying‐Ming Tsai, et al.. (2021). First-Line Anaplastic Lymphoma Kinase (ALK) Inhibitors for ALK-Positive Lung Cancer in Asian Populations: Systematic Review and Network Meta-Analysis. Journal of Clinical Medicine. 10(19). 4376–4376. 10 indexed citations
6.
Tsai, Yu-Chen, Hsiao‐Ling Chen, Kuan‐Li Wu, et al.. (2021). Salvage Therapy for Relapsed Malignant Pleural Mesothelioma: A Systematic Review and Network Meta-Analysis. Cancers. 14(1). 182–182. 18 indexed citations
7.
Chuang, Cheng‐Hao, Hsiao‐Ling Chen, Yu-Chen Tsai, et al.. (2021). Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer. Cancers. 13(8). 1966–1966. 37 indexed citations
8.
Kuo, Chia‐Yu, et al.. (2021). Increased risk of major depressive disorder in sleep apnea patients in Taiwan. Scientific Reports. 11(1). 765–765. 11 indexed citations
9.
Lin, Yen‐Ting, Chi‐Lu Chiang, Jen‐Yu Hung, et al.. (2021). Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non–small-cell lung cancer: a multicenter study using targeted next-generation sequencing. European Journal of Cancer. 156. 1–11. 25 indexed citations
10.
Wu, Ju‐Hui, Kun‐Tsung Lee, Chia‐Yu Kuo, et al.. (2020). The Association between Temporomandibular Disorder and Sleep Apnea—A Nationwide Population-Based Cohort Study. International Journal of Environmental Research and Public Health. 17(17). 6311–6311. 19 indexed citations
11.
Tsai, Ying‐Ming, Kuan‐Li Wu, Wei‐An Chang, et al.. (2020). Loss of miR-145-5p Causes Ceruloplasmin Interference with PHD-Iron Axis and HIF-2α Stabilization in Lung Adenocarcinoma-Mediated Angiogenesis. International Journal of Molecular Sciences. 21(14). 5081–5081. 17 indexed citations
12.
Yang, Chih‐Jen, Ming‐Ju Tsai, Jen‐Yu Hung, et al.. (2017). The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations. BMC Pharmacology and Toxicology. 18(1). 82–82. 32 indexed citations
13.
Hsu, Ya‐Ling, Jen‐Yu Hung, Wei‐An Chang, et al.. (2017). Hypoxic Lung-Cancer-Derived Extracellular Vesicle MicroRNA-103a Increases the Oncogenic Effects of Macrophages by Targeting PTEN. Molecular Therapy. 26(2). 568–581. 179 indexed citations
14.
15.
Yang, Chih‐Jen, Ming‐Ju Tsai, Jen‐Yu Hung, et al.. (2016). Poorer prognosis in Taiwanese female ever smokers with stage IV lung adenocarcinoma who were readministered a tyrosine kinase inhibitor. OncoTargets and Therapy. 9. 1511–1511. 10 indexed citations
16.
Tsai, Ming‐Ju, Ping‐Hsun Wu, Chau‐Chyun Sheu, et al.. (2016). Cysteinyl Leukotriene Receptor Antagonists Decrease Cancer Risk in Asthma Patients. Scientific Reports. 6(1). 23979–23979. 45 indexed citations
17.
Hsu, Ya‐Ling, Ming‐Shyan Huang, Chih‐Jen Yang, et al.. (2011). Lung Tumor-associated Osteoblast-derived Bone Morphogenetic Protein-2 Increased Epithelial-to-Mesenchymal Transition of Cancer by Runx2/Snail Signaling Pathway. Journal of Biological Chemistry. 286(43). 37335–37346. 68 indexed citations
18.
Kuo, Po‐Lin, Ming Huang, Shiyuan Huang, et al.. (2010). Signalling pathway of isophorone diisocyanate-responsive interleukin-8 in airway smooth muscle cells. European Respiratory Journal. 37(5). 1226–1236. 8 indexed citations
19.
Tsai, Jong‐Rung, et al.. (2003). Primary Malignant Fibrous Histiocytoma of the Lung: A Case Report. The Kaohsiung Journal of Medical Sciences. 19(8). 428–431. 3 indexed citations
20.
Kishimoto, Yui, Kenji Sugio, Jen‐Yu Hung, et al.. (1995). Allele-Specific Loss in Chromosome 9p Loci in Preneoplastic Lesions Accompanying Non-Small-Cell Lung Cancers. JNCI Journal of the National Cancer Institute. 87(16). 1224–1229. 166 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiang Long Breakdown of academic impact, for papers by Jian Zhou Breakdown of academic impact, for papers by Francesca Collina Breakdown of academic impact, for papers by Fangxuan Li Breakdown of academic impact, for papers by Jun Song Breakdown of academic impact, for papers by Zhijun Zhou Breakdown of academic impact, for papers by Jun Qian Breakdown of academic impact, for papers by Mahdi Abdoli Shadbad
Rankless by CCL
2026